Phase 2 N=42 BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
Melanoma
Primary: Overall Response Rate — 25.0 percentage of participants — p=<0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=630 Literacy Promotion for Latinos Study
Language Development · Behavior, Child · Parenting
Primary: Child Language Skills — 2.1; 2.3; 2.6 score on a scale — p=0.64
N/A N=38 Study of a Behavioral Intervention for Older Advanced Cancer Patients and Their Caregivers
Cancer, Advanced · Cognitive Impairment, Mild
Primary: Proportion of Dyads That Complete the Study — 12 Dyads
Phase 3 N=614 Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis
Complicated Urinary Tract Infection · Acute Pyelonephritis · cUTI
Primary: Proportion of Patients Who Achieve Composite Clinical and Microbiological Success at TOC (Test of Cure Visit) in the Microbiological Modified Intent-to-Treat (m-MITT)…
Phase 3 N=216 Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults
Tourette Disorder
Primary: Time From Randomization to Relapse in Participants Greater Than and Equal to (>=) 6 and Less Than (<) 18 Years During the Double-Blind R/WD — NA; 4.0 weeks
N/A N=58 Molecular Mechanisms of Exercise Benefits to Insulin Resistant People
Insulin Resistance · Obesity
Primary: Change in Muscle Strength — 0.37; -0.2 Ratio
Phase 2 N=109 A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
Psoriasis
Primary: Percentage of Participants Achiving PASI-75 at Week 12 — 3.6; 47.8; 80.8; 63.0 Percentage
Phase 2 N=43 QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
Colorectal Cancer · Lung Cancer · Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
N/A N=205 Pasos Hacia La Salud - Physical Activity Intervention for Latinas
Inactivity
Primary: Total Weekly Minutes of Physical Activity as Measured by the 7-Day PAR (Physical Activity Recall), From Baseline to 6-months and 12-months. — 8.01; 10.44; 112.83; 63.04…
N/A N=53 Use of Two Dissolvable Therapeutics Under Removable Partial Dentures
Edentulous Jaw · Edentulous Mouth
Primary: Change From Baseline in Patient Comfort for as Assessed by Numerical Scale. — 0.99; 1.16 units on a scale
N/A N=53 Investigation of Wearing Compliance of Spectacles for Myopia Control
Myopia
Primary: Overall Wearing Pattern of Myopia Control Spectacles — 12.8 Hours in a day
N/A N=344 Bright IDEAS - Young Adults Problem-Solving Skills Training
Cancer Patients · Young Adult · Supportive Care
Primary: Change in Symptoms of Depression, as Measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Short-Form (v1.0 8a) — -2.92; 0.31…
N/A N=16 Support Via Technology: Living and Learning With Advancing FTD
Caregivers Burnout · Frontotemporal Dementia
Primary: Revised Memory and Behavior Problems Checklist (RMBPC) — 28.5; 25.2; 16.6; 15.8 units on a scale
Phase 3 N=174 A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
Diabetic Retinopathy
Primary: Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study-Diabetic Retinopathy Severity Scale (ETDRS-DRSS) at…
N/A N=20 Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH
Treatment of Benign Prostatic Hyperplasia
Primary: Ablation Time — 36.0 Minutes